Cancer affects everyone the young and old, the rich and poor, men, women and children and represents a tremendous burden on patients, families and societies. Cancer is one of the leading causes of death in the world. Normal cells are constantly dividing, but in...
During 2015 the patent Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.
Results from a Czech Republic study. Breast cancer represents 24 % of all cancer occurring in women. Breast cancer is the most common malignancy and the second most frequent cause of death by cancer in women. Although the incidence rate of breast cancer has been...
International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test. The results from this...
Results from a published multicenter study The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow. Urine samples were...
The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was...
Result from a new German multicenter study At this years EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital,...
TUBEX® is getting wider recognition and awareness Now on social Media. As an example has one of our partners, PT. Pacific Biotekindo Intralab during the autumn organized a photo contest named TUBEX® & Me among the users of TUBEX® TF in Indonesia....
IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU. MonoTotal® is used for diagnosis, prognosis and therapy monitoring of lung cancer. MonoTotal® has previously only been...
Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples. Common rapid tests for the early detection of bladder cancer are limited to simple positive or negative results and some of...
